That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
Cannabidiol has antipsychotic effects. The exact cause for these effects is not clear. But cannabidiol seems to prevent the breakdown of a chemical in the brain that affects pain, mood, and mental function. Preventing the breakdown of this chemical and increasing its levels in the blood seems to reduce psychotic symptoms associated with conditions such as schizophrenia. Cannabidiol might also block some of the psychoactive effects of delta-9-tetrahydrocannabinol (THC). Also, cannabidiol seems to reduce pain and anxiety.
The endocannabinoid system is found in all mammals, and is made up of millions of cannabinoid receptor sites (CB1 and CB2 receptors) located throughout the body. The endocannabinoid system is one of the regulatory systems in the human body, but most people do very little to support the health of this system, because cannabinoids have not been part of the average diet. If you would like to know more about the technical aspects of the endocannabinoid system, you can go here.
REM Behavior Disorder: REM behavior disorder (RBD) is a parasomnia disorder characterized by shouting, becoming physically agitated, or otherwise acting out during sleep. For many, RBD is a symptom of a larger, more serious condition or disorder, such as Alzheimer’s disease or PTSD. CBD oil minimizes the symptoms of RBD, and also alleviates the anxiety and painful symptoms that often accompany disorders that lead to RBD.
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.